Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Comparison of different prognostic scores for patients with cirrhosis hospitalized with SARS-CoV-2 infection

Manuel Mendizabal a, b, * , Ezequiel Ridruejo b, c, Federico Piñero a, b , Margarita Anders b, d , Martín Padilla e, Luis G. Toro f, Aldo Torre g , Pedro Montes h , Alvaro Urzúa i, Esteban Gonzalez Balleraga j, María Dolores Silveyra k, Douglas Michelato l, Javier Díaz m, Mirta Peralta b, n, Joseﬁna Pages a, b, Sandro Ruiz García p, Isabel Gutiérrez Lozano q, Yuridia Macias r, Daniel Cocozella b, t, Norberto Chavez-Tapia s, Martín Tagle t, Alejandra Domínguez u, Adriana Varón b, v, Emilia Vera Pozo w, Fátima Higuera-de la Tijera x, Carla Bustios y, Damián Conte z, Nataly Escajadillo A, Andrés J Gómez B, Laura Tenorio m, Mauricio Castillo Barradas C, María Isabel Schinoni b, D, Fernando Bessone E, Fernando Contreras F, Leyla Nazal G, Abel Sanchez H, Matías García E, Julia Brusetti k, María Cecilia Cabrera h, Godofino Miranda-Zazueta g, German Rojas l, Maximo Cattaneo l, Graciela Castro-Narro s, Fernando Rubinstein l, Marcelo O. Silva a, b

a Hepatology and Liver Transplant Unit, Hospital Universitario Austral, Universidad Austral, Pilar, Argentina
b Department of Hepatology, Hospital Universitario Austral, Avenida Juan D. Perón 1500, Pilar, B1629AHJ Provincia de Buenos Aires, Argentina
c Latin American Liver Research Educational and Awareness Network (LALREAN)
d Liver Section, Centro de Educación Médica e Investigaciones Clínicas, Buenos Aires, Argentina
e Hepatology and Liver Transplant Unit, Hospital Alemán, Buenos Aires, Argentina
f Department of Gastroenterology, Hospital Nacional Guillermo Almenara Irigoyen, Lima, Perú

* Corresponding author at: Unidad de Hígado y Trasplante Hepático, Hospital Universitario Austral, Avenida Juan D. Perón 1500, Pilar, B1629AHJ Provincia de Buenos Aires, Argentina.
E-mail address: mmendiza@hospitalaustral.edu.ar (M. Mendizabal).

https://doi.org/10.1016/j.aohep.2021.100350
1665-2681/© 2021 Fundación Clínica Médica Sur, A.C. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), responsible for the coronavirus disease 2019 (COVID-19), causes substantial pulmonary disease [1]. Patients with increased age and preexisting comorbid conditions, such as diabetes and obesity, are at increased risk of death [1]. Chronic liver disease and cirrhosis are common conditions presenting a systemic immunocompromised status [2]. Thus, bacterial infections are a common cause of liver-related complications in patients with cirrhosis [3]. Viral infections have been less described in this population. In a recent study from India, 82% of patients with cirrhosis and A/H1N1/09 infection died of pneumonia and acute respiratory distress syndrome (ARDS), with bacterial or fungal infection in some cases [4]. Circulating cytokines and chemokines have been proposed to further contribute to hepatocyte and endothelial damage and the consequent hepatic decompensation [5].

SARS-CoV-2 infection in patients with cirrhosis has been associated with detrimental outcomes. We know from different retrospective studies that mortality in this population is high, ranging from 16% to 42% [6–10]. A large international study identified greater age and alcohol-related liver disease as risk factors for death in patients with cirrhosis hospitalized for COVID-19 [9]. As expected, high rates of acute hepatic decompensation and acute-on-chronic liver failure (ACLF) were also observed in patients with cirrhosis and SARS-CoV-2 infection [7–9]. However, the prognostic performance of different scoring systems to predict mortality in patients with cirrhosis have not been completely evaluated.

COVID-19 pandemic has affected later in Latin America, giving us the unique opportunity to build a multinational prospective registry. Abnormal liver tests on admission were independently associated with increased mortality in patients with no history of liver disease [11]. Thus, we now sought to evaluate the impact of COVID-19 on the clinical outcome of hospitalized patients with cirrhosis and compare different prognostic scores ability to predict patient survival.

2. Patients

2.1. Study design, setting and participating centers

This prospective cohort study was performed from April 15, 2020 through September 15, 2020 in 38 Hospitals from Argentina, Brazil, Chile, Colombia, Dominican Republic, Ecuador, Guatemala, Mexico, Paraguay, Peru and Uruguay. The study was supported and coordinated by the Latin American Association for the Study of the Liver, Viral Hepatitis Group of Interest and registered in an open public registry (NCT04358380; www.clinicaltrials.gov). Each Ethics Committee from all the participating centers approved the study protocol, following the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines [12]. The study followed ethical standards (institutional and national) and those mandated by the Helsinki Declaration of 1975, as revised in 2008. Authors had access to the study data, reviewed, and approved the final version of this manuscript.

2.2. Cohort characteristics and study variables

Eligibility criteria for enrolment included patients ≥17 years old, hospitalized with SARS-CoV-2 infection confirmed by the real-time
polymerase method (RT-PCR) as per the local site-specific protocol. In asymptomatic cases, a nasopharyngeal swab was obtained according to each country surveillance algorithm (i.e., contact with positive subjects). We also included patients admitted for a different condition and tested positive for COVID-19 during their hospitalization. Patients with high-clinical and epidemiological suspicion of SARS-CoV-2 without RT-PCR testing, those with solid organ transplantation, or pregnant were excluded. All eligible patients were enrolled at each clinical site. Cirrhosis and its etiology was determined by the site investigator or treating physician based on liver biopsy, liver elastography or a combination of clinical signs of portal hypertension (i.e. presence of gastroesophageal varices on endoscopy), biochemical parameters (i.e. presence of a platelet count less than 100,000/mm^3) and/or radiologic findings consistent with cirrhosis (i.e. splenomegaly (spleen larger than 120 mm on radiographic imaging) [13]. Study data were prospectively registered into a web-based electronic system. All patients were followed until discharge or death. Baseline exposure variables were collected for all enrolled subjects, including detailed demographic data, laboratory parameters and comorbid conditions. We also recorded the hospital course, and treatment regimens.

2.3. Liver disease evaluation

Severity of liver disease was evaluated according to Child-Turcotte-Pugh (CTP) score, model for end-stage liver disease (MELD), and MELD-Na. Patients with cirrhosis who developed ascites, variceal bleeding or hepatic encephalopathy were classified as having acute decompensation. Acute-on-chronic liver failure (ACLF) was prospectively defined according to the European Association for the Study of the Liver Chronic Liver Failure (CLIF) consortium definition and by the North American Consortium for the Study of End-Stage Liver Disease (NACELD) [3,14]. The Asian Pacific Association for the Study of the Liver ACLF criteria was not comprised in our analysis. This score includes patients without cirrhosis and excludes those with previous hepatic decompensation [15]. Thus, for each patient with cirrhosis who developed ACLF, NACELD and CLIF-C scores were considered.

To assess the impact of SARS-CoV-2 infection on clinical outcomes of hospitalized patients with cirrhosis, we compared clinical data, laboratory features, and survival of this cohort with that of a control group that included patients hospitalized with COVID-19 infection and no history of liver disease.

2.4. COVID-19 severity

The severity of COVID-19 was classified based on clinical examination results, symptoms, chest radiography and medical support. Severe COVID-19 cases were defined as those who developed ARDS, required intensive care unit (ICU) monitoring, and/or ventilatory support as reported elsewhere [6].

2.5. Primary outcome and statistical analysis

Categorical data were compared using Fisher's exact test (2-tailed) or Chi-square (X^2) test as appropriate. Continuous variables were reported with a mean (± standard deviation, SD) or median (Interquartile ranges 25–75%, IQR) and compared with Student’s T or Mann-Whitney U tests according to their respective distributions. Multivariable logistic regression was used to evaluate the association between cirrhosis and the odds of death (OR) with corresponding 95% confidence intervals (CI). We first fit univariate models to evaluate crude effects on mortality of prior medical history, clinical and laboratory findings on admission, then outcomes and treatment prescribed during hospitalization. We constructed the final multivariable models including exposure variables with a P-value <0.1 in univariate analysis, using a step-by-step procedure, in order to develop a parsimonious model. The final model's performance was evaluated including calibration (Hosmer-Lemeshow goodness-of-fit test) and discrimination power through the area under the receiving operator curve (AUROC).

We also used AUROC to determine the score accuracy (c-statistic) of baseline CTP score, MELD-Na, CLIF-C organ failure score and NACELD, as predictors of 28 days in-hospital mortality in patients with cirrhosis. Data were analyzed with STATA 13.0 (StataCorp, Texas, USA).

3. Results

A cohort of 2286 patients hospitalized with SARS-CoV-2 infection were enrolled in the Latin American Association for the Study of the Liver registry. After excluding pregnant patients (n = 26) and those who underwent solid organ transplantation (n = 45), 2211 remained for the analysis (Supplementary Fig. 1). Overall, 4.6% (CI 3.7–5.6) subjects had cirrhosis (n = 96). From the entire cohort, 8.6% (CI 7.2–9.6) were admitted for other causes and acquired SARS-CoV-2 infection during hospitalization (n = 186), including 7 patients with cirrhosis (7.3%). Baseline characteristics of the study population are displayed in Table 1. Radiological signs on admission showed pneumonia in 73.9% of the cohort (n = 1636). Common signs and symptoms reported by patients are presented in Supplementary Table 1. Ninety-seven (4.4%) patients were asymptomatic at presentation.

3.1. Clinical features of patients with cirrhosis

When compared to admitted patients without cirrhosis, patients with cirrhosis were older (53.8 ± 17.4 vs. 63.8 ± 12.5 years old; P < .0001), a higher proportion had diabetes (18.3% vs. 45.6%; P < .0001) and reported history of tobacco use (20.3% vs. 30.2%; P = 0.01) (Table 1). The most common etiologies of cirrhosis were non-alcoholic steatohepatitis in 44 patients, alcohol-induced in 22 cases, chronic hepatitis C in 6 individuals and cholestatic diseases in 5 subjects (Table 2). Baseline CTP class on admission was assessed in 93 patients: CTP-A (23%), CTP-B (45%) and CTP-C (32%); median MELD was 15 (IQR 10–22) and median MELD-Na score was 19 (IQR 14–25). On admission, 15% patients were enlisted for liver transplantation (n = 14) and some grade of encephalopathy or ascites was present in 51.1% and 42.7% of the patients; respectively (Table 2).

3.2. Clinical outcomes of patients with cirrhosis

The cumulative mortality rate in the overall cohort was 17.7% (CI 16.1–19.3) after a median time since admission of 12 (IQR 6–20) days (n = 391). Mortality was significantly higher in patients with cirrhosis compared to those without cirrhosis (46.5% vs. 16.4%; P < .0001; respectively) (Fig. 1). From the 46 patients with cirrhosis who died, the cause of death was secondary to COVID-19 lung disease in 36 (78.2%) and liver–related in 10 (21.8%) cases. Of those patients with cirrhosis who died, 4 acquired SARS-CoV-2 infection during hospitalization. Mortality rates in patients with cirrhosis increased according to CTP class; CTP-A (23.8%), CTP-B (40.5%) and CTP-C (66.7%). Patients with cirrhosis required more ICU-level care (P < .0001), developed more frequently severe COVID-19 during hospitalization (60.4% vs. 46.8%, P < .0001), and required more days of hospitalization (13.5 [IQR 7–22] vs. 9 [IQR 5–15], P = 0.0005). Thirty-four patients with cirrhosis received invasive ventilation, 24 (70.6%) for ARDS and 10 (29.4%) for encephalopathy progression. Clinical outcomes are described in Fig. 2.

During hospitalization, antibiotics were more commonly administered to patients with cirrhosis than those without cirrhosis (84.4% vs. 62.7%, P < .0001; respectively). Antiviral therapy with
Table 1
Baseline characteristics of patients hospitalized for COVID-19.

| Variable                           | Total N = 2211 | No cirrhosis N = 2115 | Cirrhosis N = 96 | P Value |
|------------------------------------|----------------|-----------------------|------------------|---------|
| Age, years (mean, ±SD)             | 54.3 (17.3)    | 53.8 (17.4)           | 63.8 (12.5)      | <.001   |
| Male sex, n (%)                    | 1328 (60.6)    | 1297 (61.3)           | 58 (60.4)        | 0.013   |
| Comorbidities, n (%)               |                |                       |                  |         |
| Hypertension                       | 708 (32.0)     | 700 (33.1)            | 38 (39.6)        | 0.109   |
| Diabetes                           | 414 (18.7)     | 388 (18.3)            | 45 (45.6)        | <.001   |
| COPD/Asthma                        | 169 (7.4)      | 163 (7.7)             | 6 (6.2)          | 0.639   |
| Cardiac disease                    | 179 (8.1)      | 169 (8.0)             | 13 (13.5)        | 0.043   |
| Cerebrovascular disease            | 54 (2.4)       | 51 (2.4)              | 3 (3.1)          | 0.621   |
| HIV                                | 21 (0.9)       | 18 (0.8)              | 3 (3.1)          | 0.023   |
| Chronic kidney disease             | 97 (4.4)       | 100 (4.7)             | 6 (6.2)          | 0.089   |
| Body Mass Index > 30               | 383 (17.3)     | 378 (17.9)            | 21 (21.9)        | 0.195   |
| Tobacco use, n (%)                 | 440 (19.9)     | 429 (20.3)            | 29 (30.2)        | 0.014   |
| Ferritin ng/mL, median (IQR)a      | 567 (223–1105) | 535 (232–1088)        | 542 (226–1625)   | 0.002   |
| C-Reactive Protein mg/dL, mean (IQR)b | 15.4 (3.4–80) | 14.9 (3.1–80)         | 36.5 (9.2–79.7)  | 0.005   |

Abbreviation: COPD, chronic obstructive pulmonary disease; HIV, human immunodeficiency virus.

Fig. 1. 28-day cumulative survival of patients with and without cirrhosis.

Fig. 2. Clinical outcomes of SARS-CoV-2 infection in patients with and without cirrhosis.
lopinavir/ritonavir was only used in the group of patients without cirrhosis (7.6% vs. 0%; \( P = 0.001 \)). Overall, the proportion of patients receiving COVID-targeted therapy was significantly higher in those with cirrhosis compared to those without cirrhosis (98.9% vs. 76.6%; \( P < 0.0001 \); respectively). Treatment received by hospitalized patients with COVID-19 are reported in Supplementary Table 2.

### 3.3. Association of cirrhosis with death

We evaluated the effect of cirrhosis on the risk of mortality adjusted for other variables previously described to be associated with death. Baseline factors significantly associated with death by univariable analysis were age >65 years (OR 7.8; CI 5.7–10.7; \( P < 0.0001 \)), male gender (OR 1.5; CI 1.2–1.9; \( P = 0.0003 \)), hypertension (OR 2.2; CI 1.7–2.7; \( P < 0.0001 \)), diabetes (OR 2.1; CI 1.6–2.7; \( P < 0.0001 \)), cardiac disease (OR 2.1; CI 1.5–2.9; \( P < 0.0001 \)), chronic kidney disease (OR 3.8; CI 2.5–5.8; \( P < 0.0001 \)), BMI >30 (OR 1.5; CI 1.1–1.9; \( P < 0.0001 \)) and cirrhosis (OR 4.5; CI 2.9–6.8; \( P < 0.0001 \) (Table 3). Regarding the etiology of liver disease, we found no association with mortality (data not shown). Multivariable analysis of factors associated with death demonstrated persisting association between age >65 years (OR 7.2, 5.2–10.0; \( P < 0.0001 \)), male gender (OR 1.8, CI 1.4–2.3; \( P < 0.0001 \)), BMI >30 (OR 1.7, CI 1.3–2.3; \( P < 0.0001 \)) and cirrhosis (OR 3.1, CI 1.9–4.8; \( P < 0.0001 \) (Table 3). The model showed adequate calibration (\( P = 0.1 \)) with an AUROC of 0.75 (CI 0.73–0.77).

### 3.4. Acute decompensation and acute-on-chronic liver failure

Within the 96 patients with cirrhosis, acute decompensation events or worsening of baseline clinical condition following hospitalization for SARS-CoV-2 infection were reported in 59 (61.4%) cases. Decompensation events included new or worsening encephalopathy 43 (48.3%), ascites 34 (38.2%) and variceal hemorrhage 28 (31.4%). Among the whole cirrhosis cohort, 53 (55.2%) and 29 (30%) patients developed ACLF according to CLIF-C organ failure score and NACELD, respectively (Supplementary Fig. 1). We used AUROC to assess the ability of scoring systems to predict 28-days mortality in patients with cirrhosis following hospitalization for SARS-CoV-2 infection. The AUROC of CLIF-C organ failure score (AUROC 0.85, CI 0.78–0.91) had better prognostic accuracy than CTP score (AUROC 0.67, CI 0.56–0.78), baseline MELD-Na (AUROC 0.75, CI 0.73–0.77) with a median follow-up of 17 days (IQR 7–34).
Table 3
Logistic regression analysis for the primary outcome (death) evaluating prior medical history. Odds Ratios (OR).

| Baseline Exposure variable | Mortality rate (95% CI) | Crude OR (95% CI) | P | Adjusted OR (95% CI) | P |
|---------------------------|-------------------------|------------------|---|---------------------|---|
| Age, years                |                         |                  |   |                     |   |
| <50                       | 6.1% (5.8–6.4)          | –                | – | –                   | – |
| 50–65                     | 17.0% (14.1–20.2)       | 3.1 (2.2–4.4)    | .001 | 2.8 (1.9–4.0) | <.001 |
| >65                       | 33.9% (30.2–37.5)       | 7.8 (5.7–10.7)   | <.001 | 7.2 (5.2–10.0) | <.001 |
| Gender                    |                         |                  |   |                     |   |
| Female                    | 14.1% (10.3–14.8)       | –                | – | –                   | – |
| Male                      | 20.3% (18.1–22.5)       | 1.5 (1.2–1.9)    | <.001 | 1.8 (1.4–2.3) | <.001 |
| Hypertension              |                         |                  |   |                     |   |
| Yes                       | 25.9% (22.9–32.1)       | 2.2 (1.7–2.7)    | <.001 | –                   | – |
| No                        | 13.8% (12.1–15.6)       | –                | – | –                   | – |
| Diabetes mellitus         |                         |                  |   |                     |   |
| Yes                       | 27.8% (23.5–32.3)       | 2.1 (1.6–2.7)    | <.001 | –                   | – |
| No                        | 15.3% (13.7–17.1)       | –                | – | –                   | – |
| COPD/Asthma               |                         |                  |   |                     |   |
| Yes                       | 20.9% (15.0–27.9)       | 1.2 (0.8–1.8)    | 0.192 | –                   | – |
| No                        | 17.4% (15.8–19.1)       | –                | – | –                   | – |
| Cardiac disease           |                         |                  |   |                     |   |
| Yes                       | 29.6% (23.0–36.8)       | 2.1 (1.5–2.9)    | <.001 | –                   | – |
| No                        | 16.6% (14.9–18.2)       | –                | – | –                   | – |
| Cerebrovascular disease   |                         |                  |   |                     |   |
| Yes                       | 25.0% (14.9–39.5)       | 1.6 (0.9–3.1)    | 0.102 | –                   | – |
| No                        | 17.5% (15.9–19.1)       | –                | – | –                   | – |
| HIV                       |                         |                  |   |                     |   |
| Yes                       | 19.0% (5.4–41.9)        | 1.1 (0.3–3.3)    | 0.808 | –                   | – |
| No                        | 17.7% (15.9–19.1)       | –                | – | –                   | – |
| Cancer                    |                         |                  |   |                     |   |
| Yes                       | 20.6% (13.3–29.4)       | 1.6 (0.9–2.9)    | 0.103 | –                   | – |
| No                        | 17.5% (15.9–19.1)       | –                | – | –                   | – |
| Chronic kidney disease    |                         |                  |   |                     |   |
| Yes                       | 43.3% (13.1–30.0)       | 3.8 (2.5–5.8)    | <.001 | –                   | – |
| No                        | 16.5% (14.9–18.1)       | –                | – | –                   | – |
| Rheumatologic disease     |                         |                  |   |                     |   |
| Yes                       | 20.6% (8.7–37.9)        | 1.2 (0.5–2.8)    | 0.655 | –                   | – |
| No                        | 17.6% (16.0–19.2)       | –                | – | –                   | – |
| Body mass index > 30      |                         |                  |   |                     |   |
| Yes                       | 22.9% (16.6–25.0)       | 1.5 (1.1–1.9)    | 0.003 | 1.7 (1.3–2.3) | <.001 |
| No                        | 16.6% (14.9–18.3)       | –                | – | –                   | – |
| Tobacco Active/Pass        |                         |                  |   |                     |   |
| Yes                       | 22.3% (18.4–26.4)       | 1.0 (0.8–1.3)    | 0.798 | –                   | – |
| No                        | 16.5% (14.7–18.3)       | –                | – | –                   | – |
| Cirrhosis                 |                         |                  |   |                     |   |
| Yes                       | 46.9% (36.6–57.3)       | 4.5 (2.9–6.8)    | <.001 | 3.1 (1.9–4.8) | <.001 |
| No                        | 19.5% (17.8–21.2)       | –                | – | –                   | – |

Note: Calibration P = 0.1 (Hosmer-Lemeshow) and discrimination for this model was ROC 0.75 (CI 0.73–0.77).

Table 4
Ability of four scoring systems to predict 28-days mortality in patients with cirrhosis following hospitalization for SARS-CoV-2 infection.

| Score          | ROC (95% CI) | Sensitivity | Specificity | PPV | NPV |
|----------------|-------------|-------------|-------------|-----|-----|
| CLIF-C         | 0.85 (0.78–0.91) | 97%         | 72%         | 79  | 95  |
| NACELD         | 0.75 (0.66–0.84) | 99%         | 99%         | 99  | 99  |
| MELD-Na        | 0.69 (0.58–0.80) | 79%         | 79%         | 79  | 95  |
| CTP            | 0.67 (0.56–0.78) | 73%         | 73%         | 73  | 73  |

Abbreviations: CLIF-C, Chronic Liver Failure Consortium; CTP, Child-Turcotte-Pugh; LR, log likelihood ratio; MELD-Na, model for end-stage liver disease; NACELD, North American Consortium for the Study of End-stage Liver Disease; NPV, negative predictive value; PPV, positive predictive value.

0.70, CI 0.58–0.80), and NACELD (AUROC 0.75, CI 0.66–0.84) (Fig. 3). The AUROCs estimated for the CLIF-C organ failure score, CTP score, MELD-Na and NACELD were compared in pairs and were significantly different for all cases (P = 0.009). Sensitivity, specificity, positive predictive value and negative predictive value of the four different scores regarding 28-days mortality rate are demonstrated in Table 4.

4. Discussion

The results from this large Latin American prospective cohort study describe that patients with cirrhosis hospitalized with COVID-19 were more frequently admitted to ICU and had a significantly higher probability of developing severe COVID-19 than those individuals without cirrhosis. Moreover, patients with cirrhosis presented 3-fold increased mortality risk than those with no liver disease. Additionally, a high proportion of patients with cirrhosis developed either acute decompensation or ACLF. When comparing different scores to predict 28-day mortality in a head-to-head manner we found that CLIF-C definition has the better prognostic performance in this population.

Our observed mortality rate was strikingly higher than the rate reported in recently published studies from Europe and North America (30–34%) and similar to a small cohort from India (42%) [7–9]. We can speculate that this might be the consequence of treating patients with advanced liver disease and multi-organ failure in a region with a fragile health care system. Despite this potential limitation, infected patients with cirrhosis have a uniformly worse crude prognosis compared to uninfected patients [3]. Whether SARS-CoV-2 infection outcomes are similar to other acute precipitants, including bacterial infection in patients developing ACLF, remains uncertain. A study from Italy reported significantly higher mortality in patients with cirrhosis and SARS-CoV-2 compared with bacterial infection [7]. Viral infections in patients with cirrhosis have also been associated with high mortality rates. Influenza virus infection has been associated with an 18% mortality rate in patients with cirrhosis [16]. Furthermore, in a study from India,
18 out of 22 patients with H1N1 infection and cirrhosis died of pneumonia and ARDS [4]. These studies underscore the concept that infections are associated with ACLF and excessive systemic inflammation leading to organ dysfunction through direct deleterious effects on microcirculatory homeostasis and mitochondrial function [17]. The accepted strategy for the management of ACLF is treating the precipitating factor whilst providing intensive monitoring and support of failing organs [18]. Specific treatment against SARS-CoV-2 was not standardized in our study. However, we did not find any specific therapy associated with increased survival (data not shown).

Our observed rates of patients with cirrhosis and advanced liver disease (CTP B–C 77%) far exceeded the previously reported by the SECURE-cirrhosis registry (CTP B–C 56%) and by a study from Italy (CTP B–C 62%) [7,9]. We can speculate that this could be the consequence of many factors such as the strict and prolonged quarantine established in many Latin American countries that precluded patients with cirrhosis to be adequately monitored; the scarce availability of beds in the ICU in many cities despite having more time than Europe to condition the health system, and the SARS-CoV-2 infection that led to a rapid clinical deterioration of patients with cirrhosis. Only 33% of hospitalized patients with CTP-C cirrhosis survived, and mortality further increased in those receiving mechanical ventilation. The pandemic represents a challenging scenario for patients with cirrhosis and their treating physicians. We report a strong association between liver disease severity and death after SARS-CoV-2 infection, highlighting the importance of carefully monitoring these patients guided by individual risk, institutional resources and the local burden of COVID-19.

In line with previous studies, we described lung injury as the predominant cause of death in patients with cirrhosis [7,9]. Liver-related complications accounted for only 22% of mortality in patients with cirrhosis from our cohort. Nevertheless, respiratory function had been severely compromised by SARS-CoV-2 since all of them required invasive ventilation. Severe ARDS was significantly more common in patients with cirrhosis compared with those without liver disease. This implicates liver dysfunction as a potential driver of ongoing lung injury. The mechanism for enhanced lung injury in patients with cirrhosis is probably multifactorial. It may include altered pulmonary function through worsening ascites or hepatic hydrothorax, impaired coagulation associated with venous thromboembolic disease and immune dysregulation.

We evaluated the performance of different prognostic scores to determine mortality at 28-days in patients with cirrhosis. In our study, CLIF-C definition of ACLF has the best prognostic performance compared to NACSELD, MELD, and CTP. Moreover, the use of CLIF-C definition led to the diagnosis of a larger number of patients with ACLF. NACSELD presented a poor sensitivity for mortality prediction that can be explained by the restrictive nature of their diagnostic criteria for ACLF. Considering that there is still no consensus on which is the best score to determine 28-day mortality in patients with ACLF, our findings are similar to those reported by a Brazilian prospective study who described that CLIF-C had better performance in predicting mortality when compared to NACSELD criteria [19]. Interestingly, in a North American cohort Bajaj et al. described the Charlson Comorbidity Index to be independently associated with mortality in patients with cirrhosis and COVID-19 [8]. Furthermore, laverone et al. have proposed that the combination of CLIF-C and Charlson Comorbidity Index better predict survival in these patients [20]. One of the greatest contributions of these scores is to determine the futility of continued aggressive care in hospitalized patients with cirrhosis [3]. In patients with four organ failures in whom survival is unlikely, escalation of care and use of palliative care should be carefully evaluated. During the COVID-19 pandemic, we have learned that health care expenditures and human resources are valuable and limited supplies.

Our study’s major strength is the inclusion of a large and geographically diverse population, in which data collection and outcome measures have been clearly defined and prospectively collected. Additionally, comparing cases with contemporaneous patients without cirrhosis strengthens the association between liver disease severity and mortality described in patients with cirrhosis. However, we are aware that our study suffers certain limitations. First, few patients have fulfilled ACLF criteria according to NACSELD definition. However, this can be the consequence of a more severe definition of organ failures. Second, some major covariables can be missing in our registry given that we prioritize clinical data and well-known factors associated with poor outcomes. Third, given our study’s design, we did not compare COVID-19-associated outcomes in patients with cirrhosis and SARS-CoV-2 infection who did not require hospitalization to those of persons without cirrhosis. Moreover, some patients with undiagnosed cirrhosis could have been incorrectly included in the group of patients with no cirrhosis. Finally, although SARS-CoV-2 infection was diagnosed as per the local site-specific protocol, algorithms followed their local epidemiological situation and available resources.

In summary, in this large multicenter cohort from Latin America, we described that SARS-CoV-2 infection in cirrhosis patients is strongly associated with high rates of acute hepatic decompensation and death. Moreover, CLIF-C definition allowed a greater number of patients to be diagnosed with ACLF and better predicted 28-day mortality compared to NACSELD, CTP, and MELD-Na. Our findings highlight the need to follow the recommended preventive measures in patients with advanced liver disease during COVID-19 pandemic [21].

Abbreviations

ACLF acute-on-chronic liver failure
ARDS acute respiratory distress syndrome
AUC area under the receiving operator curve
CLIF-C Chronic Liver Failure Consortium
COVID-19 Coronavirus disease 2019
CTP Child-Turcotte-Pugh
ICU intensive care unit
MELD model for end-stage liver disease
NACSELD North American Consortium for the Study of End-Stage Liver Disease
SARS-CoV-2 severe acute respiratory syndrome coronavirus 2

Funding

None.

Conflict of interest

None.

Authorship

Contributorship Statement: Dr. Manuel Mendizabal had full access to all of the data in the study and take responsibility for the integrity of data and accuracy of the data analysis.

Concept and design: Drs. Marcelo O. Silva and Manuel Mendizabal.

Acquisition, analysis, or interpretation of data: Drs. Manuel Mendizabal, Ezequiel Ridruejo, Federico Piñero, Margarita Anders, Martín Padilla, Luis G. Toro, Aldo Torre, Pedro Montes, Alvaro Urzúa, Esteban G. Balleraga, María D. Silveyra, Douglas Michelato,
Javier Díaz, Mirta Peralta, Josefena Pages, Sandro R. García, Isabel G. Lozano, Yuridia Macias, Daniel Cocozella, Norberto Chavez-Tapia, Martín Tagle, Alejandro Domínguez, Adriana Varón, Emilia V. Pozo, Fátima Higuera-de la Tijera, Carla Bustios, Damián Conte, Nataly Escajadillo, Andrés J. Gómez, Laura Tenorio, Mauricio Castillo Barradas, Maria Isabel Schinoni, Fernando Bessone, Fernando Contreras, Leyla Nazal, Abel Sanchez, Matías García, Julia Bruttí, María Cecilia Cabrera, Godoflino Miranda-Zazueta, German Rojas, Maximo Cattaneo, Graciela Castro-Narro, Fernando Rubinstein and Marcelo O. Silva.

Drafting of the manuscript: Dr. Manuel Mendizábal.

Critical revision of the manuscript for important intellectual content: Drs. Manuel Mendizábal, Ezequiel Rírdojte, Federico Piñero, Margarita Anders, Martín Padilla, Luis G. Toro, Aldo Torre, Pedro Montes, Alvaro Urzúa, Esteban G. Ballarga, María D. Silveyra, Douglas Michelato, Javier Díaz, Mirta Peralta, Josefena Pages, Sandro R. García, Isabel G. Lozano, Yuridia Macias, Daniel Cocozella, Norberto Chavez-Tapia, Martín Tagle, Alejandro Domínguez, Adriana Varón, Emilia V. Pozo, Fátima Higuera-de la Tijera, Carla Bustios, Damián Conte, Nataly Escajadillo, Andrés J. Gómez, Laura Tenorio, Mauricio Castillo Barradas, Maria Isabel Schinoni, Fernando Bessone, Fernando Contreras, Leyla Nazal, Abel Sanchez, Matías García, Julia Bruttí, María Cecilia Cabrera, Godoflino Miranda-Zazueta, German Rojas, Maximo Cattaneo, Graciela Castro-Narro, Fernando Rubinstein and Marcelo O. Silva.

Supervision: Ds. Rírdojte, Rubinstein, Silva.

Final approval of the version to be submitted: Ds. Manuel Mendizábal, Ezequiel Rírdojte, Federico Piñero, Margarita Anders, Martín Padilla, Luis G. Toro, Aldo Torre, Pedro Montes, Alvaro Urzúa, Esteban G. Ballarga, María D. Silveyra, Douglas Michelato, Javier Díaz, Mirta Peralta, Josefena Pages, Sandro R. García, Isabel G. Lozano, Yuridia Macias, Daniel Cocozella, Norberto Chavez-Tapia, Martín Tagle, Alejandro Domínguez, Adriana Varón, Emilia V. Pozo, Fátima Higuera-de la Tijera, Carla Bustios, Damián Conte, Nataly Escajadillo, Andrés J. Gómez, Laura Tenorio, Mauricio Castillo Barradas, Maria Isabel Schinoni, Fernando Bessone, Fernando Contreras, Leyla Nazal, Abel Sanchez, Matías García, Julia Bruttí, María Cecilia Cabrera, Godoflino Miranda-Zazueta, German Rojas, Maximo Cattaneo, Graciela Castro-Narro, Fernando Rubinstein and Marcelo O. Silva.

Statistical analysis: Ds. Manuel Mendizábal, Federico Piñero and Fernando Rubinstein.

Acknowledgements

We would like to thank ALEH’s executive office for their invaluable help and support on this project, especially to Macarena Muñoz, María Jesús Marcone and Verónica García Huidobro. To Silvina Heisecke from CEMIC-CONICET for the copypasting of this manuscript.

Other authors who collaborated with data acquisition: Jonathan Aguirre-Valadez, Silvana Ocampo, Claudio Toledo, Mauricio Orrego, Victoria Mainardi, Marcos Giralda, Beatriz Ameigeiras, Pablo Caballini, Aldana Scarpa, Kelly Stephany Casanova Lau and Jorge José Díaz Rodriguez.

Appendix A. Supplementary data

Supplementary material related to this article can be found, in the online version, at doi:https://doi.org/10.1016/j.ajhep.2021.100350.